GHRP-2
Aliases: Pralmorelin · KP-102
Last verified: 2026-09-23
The short version
A hexapeptide GH secretagogue — strong GH spike with moderate appetite and prolactin/cortisol elevation. In Japan (Pralmorelin) used as a GH-deficiency diagnostic. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically studied in Japan (approved there as a diagnostic test); therapeutic development halted. Status: discontinued. Diagnostically approved in Japan; not a therapeutic drug. WADA-banned.
Identity & type
- Molecular type
- peptide
- Origin
- A hexapeptide GH secretagogue — strong GH spike with moderate appetite and prolactin/cortisol elevation.
Mechanism of action
GHS-R1a agonist; synergistic with GHRH; partly acts via somatostatin suppression.
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100–300 mcg SC 1–3× daily on an empty stomach. A strong GH pulse with moderate hunger. Users report sleep, recovery and appetite increase; in sensitive individuals it raises prolactin and cortisol more than ipamorelin.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A strong GH pulse with moderate hunger. Users report sleep, recovery and appetite increase; in sensitive individuals it raises prolactin and cortisol more than ipamorelin.
Protocol — official vs community
Official / label
No approved product. Research GHRP with strong GH release and moderate prolactin/cortisol effects.
Duration: Study use only.
Sits between ipamorelin (clean) and hexarelin (potent, messy).
Community (anecdotal)
100–300 mcg SC 2–3× daily, stacked with a GHRH analogue.
- Cycle:
- 8–12 weeks.
- Break:
- 4 weeks off.
Some hunger stimulation — used deliberately as an appetite tool by some, avoided by others.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically studied in Japan (approved there as a diagnostic test); therapeutic development halted.
Preclinical evidence
Clinically studied in Japan (approved there as a diagnostic test); therapeutic development halted.
Known risks
- Hunger, mild prolactin/cortisol elevation, water retention.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.